

RESEARCH

Open Access



Improving astaxanthin production in *Escherichia coli* by co-utilizing CrtZ enzymes with different substrate preference

Meng Zhang^{1,2†}, Zhongkuo Gong^{2†}, Jinlei Tang^{2,3,4,5}, Fuping Lu¹, QingYan Li^{2,3,4,5*} and XueLi Zhang^{2,3,4,5*}

Abstract

Background: The bifunctional enzyme β -carotene hydroxylase (CrtZ) catalyzes the hydroxylation of carotenoid β -ionone rings at the 3, 3' position regardless of the presence of keto group at 4, 4' position, which is an important step in the synthesis of astaxanthin. The level and substrate preference of CrtZ may have great effect on the amount of astaxanthin and the accumulation of intermediates.

Results: In this study, the substrate preference of PCrtZ from *Paracoccus* sp. PC1 and PActZ from *Pantoea Agglomerans* were certified and were combined utilization for increase astaxanthin production. Firstly, PCrtZ from *Paracoccus* sp. PC1 and PActZ from *P. Agglomerans* were expressed in platform strains CAR032 (β -carotene producing strain) and Can004 (canthaxanthin producing strain) separately to identify their substrate preference for carotenoids with keto groups at 4,4' position or not. The results showed that PCrtZ led to a lower zeaxanthin yield in CAR032 compared to that of PActZ. On the contrary, higher astaxanthin production was obtained in Can004 by PCrtZ than that of PActZ. This demonstrated that PCrtZ has higher canthaxanthin to astaxanthin conversion ability than PActZ, while PActZ prefer using β -carotene as substrate. Finally, Ast010, which has two copies of PActZ and one copy of PCrtZ produced 1.82 g/L of astaxanthin after 70 h of fed-batch fermentation.

Conclusions: Combined utilization of *crtZ* genes, which have β -carotene and canthaxanthin substrate preference respectively, can greatly enhance the production of astaxanthin and increase the ratio of astaxanthin among total carotenoids.

Keywords: *Escherichia coli*, Astaxanthin, β -carotene hydroxylase, Substrate preference, Combined utilization

Background

Carotenoids are organic pigments ranging in color from yellow to red that are naturally produced by certain organisms, including photosynthetic organisms (e.g. plants, algae, cyanobacteria), as well as some nonphotosynthetic bacteria, yeast and fungi. Carotenoids such

as lutein, zeaxanthin or astaxanthin are important additives in food and feed industry as pigmenting substances and precursors of vitamin A derivatives [1–4]. In addition, carotenoids have health-promoting effects such as enhancing the immune response and, due to their antioxidant properties, anticancer activity, which makes them of interest as nutraceuticals [1, 5]. An economical process for preparing carotenoids and foodstuffs with an increased carotenoid content is therefore of great importance. Producing carotenoids by metabolic engineering of recombinant microorganisms gained increasing attention because it is environmental friendly and has a lower cost than chemical synthesis.

*Correspondence: li_qy@tib.cas.cn; zhang_xl@tib.cas.cn

[†]Meng Zhang and Zhongkuo Gong contributed equally to this work

²Tianjin Institute of Industrial Biotechnology, Chinese of Academy of Sciences, 32 Xiqidao, Tianjin Airport Economic Park, Tianjin 300308, China

Full list of author information is available at the end of the article



Astaxanthin, an important hydroxyl-carotenoid, has great potential commercial value in the feed, cosmetics, and nutraceutical industries due to its strong antioxidant capacity [6]. The heterologous synthesis pathway of astaxanthin comprises the two enzymes β -carotene ketolase (CrtW) [7] and β -carotene hydroxylase (CrtZ) [8, 9], which perform four interchangeable reactions starting from β -carotene and produce eight intermediates in addition to astaxanthin (Fig. 1). CrtZ is a bifunctional enzyme that catalyzes the hydroxylation reaction of β -carotene to yield zeaxanthin via β -cryptoxanthin, or the conversion of canthaxanthin into zeaxanthin via adonirubin [10]. These enzymes are crucial for the heterologous synthesis of hydroxyl-carotenoids, such as astaxanthin and zeaxanthin. To improve astaxanthin production, 12 β -carotene ketolases and 4 β -carotene hydroxylases from 5 cyanobacterial species were screened for astaxanthin biosynthesis in *E. coli*. The best recombinant strain reported in the literature expressed *crtZ* from *Pantoea agglomerans* and *crtW* from *Nostoc* sp. PCC 7120, producing an astaxanthin titer of 1.99 mg/g DCW [8]. Subsequently, 12 β -carotene hydroxylases genes, derived from archaea,

bacteria, cyanobacteria, and plants, were investigated for their function about astaxanthin synthesis within *E. coli*. The result showed that *crtZ* from *P. agglomerans* was found to be the most suitable for astaxanthin biosynthesis. Moreover, efficient astaxanthin biosynthesis also requires the balanced expression of β -carotene ketolase and β -carotene hydroxylase [9]. Some studies showed that the adonixanthin, a monketolated derivative of zeaxanthin, accumulated as the dominant intermediate [11, 12]. Zeaxanthin was found to be the only other detectable carotenoid in addition to astaxanthin, and reduced expression of *crtW* with respect to *crtZ* increased the efficiency of astaxanthin biosynthesis [13]. Conversely, canthaxanthin and echinenone were dominant products in addition except for astaxanthin, and their accumulation was reduced by increasing the gene copy number of *crtZ* [14]. We hypothesized that different ratios of intermediates were accumulated in the process of astaxanthin synthesis because enzymes from different sources have different substrate specificity [11–14]. The catalytic activities of 3 *crtZ* orthologs from different organisms were compared in the presence of both utilizable substrates in




Fig. 1 Schematic diagram of the heterologous synthesis pathway for the production of carotenoids. *MVA Pathway* mevalonic acid pathway, *MEP Pathway* 2-methyl-D-erythritol-4-phosphate pathway, *DMAPP* dimethylallyl pyrophosphate, *IPP* isopentenyl pyrophosphate; Genes of enzymes are as follows: *ispA*, Farnesyl pyrophosphate synthase; *crtE*, GGPP synthase; *crtB*, phytoene synthase; *crtI*, phytoene desaturase; *crtY*, lycopene cyclase; *PAcrtZ*, β -carotene hydroxylase from *P. agglomerans*; *PCcrtZ*, *Paracoccus* sp. PC1; *crtW**, mutated β -carotene ketolase; *crtZ*, β -carotene hydroxylase from *P. agglomerans* or *Paracoccus* sp. PC1

vitro [10]. The results indicated that the CrtZ enzymes from *Paracoccus* sp. PC1 (formerly known as *Alcaligenes* sp. PC-1) and *Agrobacterium aurantiacum* preferentially converted canthaxanthin to astaxanthin, while CrtZ from the *Pantoea ananatis* (formerly *Erwinia ure-dovora*) preferentially catalyzed the formation of zeaxanthin from β -carotene. The specific enzyme activity of CrtZ from *Paracoccus* sp. PC1 was 28 pmol/h/mg protein when converted canthaxanthin into astaxanthin, and was 3.4 pmol/h/mg/ protein when β -carotene as substrate. Furthermore, CrtZ from *Paracoccus* sp. PC1 showed that canthaxanthin was the favored substrate for conversion, 6-fold for canthaxanthin compared to β -carotene, when both substrates were added to the enzyme preparation in an equal ratio. However, it was still unclear whether the same substrate preference was still present *in vivo*, or if the canthaxanthin preference of CrtZ could reduce canthaxanthin accumulation and improve astaxanthin production when combined with another β -carotene hydroxylase with β -carotene propensity.

Ast007 is an astaxanthin producing strain in which *crtZ* and *crtW* (including 2 copies of *PCcrtZ* and 1 copy of *crtW**) (Table 1) were coordinately expressed. Although there are many intermediates such as β -carotene,

canthaxanthin and echinenone accumulated in Ast007, the astaxanthin yield did not increase even more copy of *crtZ* or *crtW* was added [14]. A large amount of ketolated intermediates accumulation probably implied there were not suitable β -carotene hydroxylase catalyzes the hydroxylation of carotenoid β -ionone rings with keto group. In this study, the preference of *PCcrtZ* in the conversion of canthaxanthin into astaxanthin was tested, and used to improve astaxanthin production by co-utilizing with *PAcrtZ* from *P. agglomerans* in *E. coli*.

Results

Construction of platform strains to confirm the functional expression of *crtZ*

Beta-carotene hydroxylase (CrtZ) introduces hydroxyl moieties at the 3, 3' position of the β -ionone ring irrespective of the presence or absence of a keto group at the 4, 4' position. In order to study the substrate preference of different CrtZ orthologs, platform strains that produce high levels of β -carotene (substrate without keto group) or canthaxanthin (substrate with keto group) were constructed.

The numbers indicate the peaks of carotenoids in the HPLC chromatogram: 1, β -carotene; 2, canthaxanthin; 3,

Table 1 *Escherichia coli* strains used in this work

Strains	Relative characteristics	Copies of <i>crtYZW</i> genes				Sources	
		<i>crtY</i>	PC <i>crtZ</i>	PA <i>crtZ</i>	<i>crtW*</i>		
CAR026	ATCC 8739, M1-37:: <i>dxs</i> , M1-46:: <i>idi</i> , <i>ldhA</i> ::P-trc:: <i>crtEIB::ldhA</i> , M1-46:: <i>SucAB</i> , M1-46:: <i>sdh</i> , M1-46:: <i>talB</i> , mRSL-4:: <i>ispG</i> , mRSL-14:: <i>ispH</i> , <i>pta</i> ::P-trc:: <i>crtY::pta</i> , <i>poxB</i> ::P-trc:: <i>MVA::poxB</i>	1	0	0	0	[14]	
CAR032	CAR026, <i>mgsA</i> ::P-trc:: <i>crtY</i>	2	0	0	0	This work	
Strains for producing astaxanthin							
Ast004	CAR026, <i>mgsA</i> ::P-trc:: <i>crtZW*</i>	1	0	1	1	[14]	
Ast005	CAR026, <i>mgsA</i> ::P-trc:: <i>crtYZW*</i>	2	0	1	1	[14]	
Gro-46	Ast005, <i>pflB</i> :: <i>crtZ</i> ::M1-RBSL-9, <i>gno</i> ::M1-46	2	0	2	1	[14]	
Ast014	Can004, <i>manA</i> ::P-trc:: <i>crtZ</i>	2	0	1	2	This work	
Ast015	Can004, <i>manA</i> ::P-trc:: <i>crtZ-crtZ</i>	2	0	2	2	This work	
Ast016	Can004, <i>manA</i> ::P-trc:: PC <i>crtZ</i>	2	1	0	2	This work	
Ast017	Can004, <i>manA</i> ::P-trc:: PC <i>crtZ</i> -PC <i>crtZ</i>	2	2	0	2	This work	
Ast018	Ast017, <i>pflB</i> ::P-trc::PC <i>crtZ</i>	2	3	0	2	This work	
Ast019	Ast017, <i>pflB</i> ::P-trc::PC <i>crtZ</i> -PC <i>crtZ</i>	2	4	0	2	This work	
Ast010	Gro-46, <i>manA</i> ::P-trc:: PC <i>crtZ-crtW*</i>	2	1	2	2	This work	
Strains for producing zeaxanthin							
Zea001	CAR032, <i>manA</i> ::P-trc::PC <i>crtZ</i>	2	1	0	0	This work	
Zea002	CAR032, <i>manA</i> ::P-trc::PC <i>crtZ</i> -PC <i>crtZ</i>	2	2	0	0	This work	
Zea003	CAR032, <i>manA</i> ::P-trc:: <i>crtZ</i>	2	0	1	0	This work	
Zea004	CAR032, <i>manA</i> ::P-trc:: <i>crtZ-crtZ</i>	2	0	2	0	This work	
Strains for producing canthaxanthin							
Can003	CAR026, <i>mgsA</i> ::P-trc:: <i>crtYW*</i>	2		0	0	1	This work
Can004	Can003, <i>lacZ</i> ::P-trc:: <i>crtW*</i>	2		0	0	2	This work

echinenone; 4, zeaxanthin; 5, β -cryptoxanthin; 6, adonixanthin; 7, astaxanthin; 8, lycopene.

The pathway fluxes of CAR026 were fully balanced by modular pathway optimization and β -carotene production of CAR026 reached to 3.6 g/L after 48 h of fed-batch of fermentation, with a little lycopene accumulation [14–17]. Ast004, in which one copy of *PActrZ* and a copy of *crtW** were integrated into the chromosome of CAR026 at *mgsA* site, had much more lycopene accumulation than that of CAR026, even there wasn't any modification on lycopene biosynthesis pathway [14]. A large amount of lycopene accumulation in Ast004 was due to the insufficient activity of *CrtY*. Accordingly, additional copies of *crtY* can greatly reduce the accumulation of lycopene and increase the yield of astaxanthin [14]. Therefore, the β -carotene producing stain CAR032 was constructed by inserting a copy of *crtY* gene into the chromosome of CAR026 at the *mgsA* site. The biomass and β -carotene production of CAR032 respectively decreased by 16 and 4% compared to that of CAR026 in shake flasks fermentation (Table 2; Fig. 2 A). We speculated that the β -carotene accumulation inhibited lycopene synthesis [14]. Therefore, the addition of *crtY* did not improve the production of β -carotene due to the lack of lycopene. At the same time, biomass accumulation decreased because of an increased metabolic burden. However, additional copies of *crtY* could compensate for the insufficient activity of *CrtY* when the feedback was released because the β -carotene was converted into adonirubin or zeaxanthin [14]. Consequently, CAR032 was used as a platform to


Table 2 Carotenoids production by representative *E. coli* strains

Strain ^a	OD ₆₀₀	canthaxanthin (mg/L)	echinenone (mg/L)	β -carotene (mg/L)
CAR026	6.96 ± 0.13	n.d.	n.d.	48.4 ± 3.47
CAR032	5.13 ± 0.08	n.d.	n.d.	46.51 ± 1.85
Can003	9.98 ± 0.72	26.6 ± 2.59	4.21 ± 1.73	8.62 ± 1.74
Can004	9.82 ± 0.26	40.7 ± 0.41	3.6 ± 0.65	3.87 ± 0.65

^a Three repeats were performed for each strain, and the error bars represented standard deviation

study the enzymatic properties of *CrtZ* orthologs from different organisms.

CrtW converts β -carotene into keto-carotenoids, which have a keto group at the 4, 4' position of the ionone ring, and it can be used to synthesize canthaxanthin, which in turn can be converted into astaxanthin by *CrtZ*. The canthaxanthin producing strain Can003 was constructed by inserting a *crtYW** operone at the *mgsA* site of CAR026 (Table 1). Can003 produced 26.6 mg/L of canthaxanthin, with 4.21 mg/L of echinenone and 8.62 mg/L of β -carotene as by-products (Table 2). This result demonstrated that more *CrtW* was needed to efficiently convert echinenone and β -carotene into canthaxanthin. An additional copy of *crtW** was inserted into the chromosome at the *lacZ* site. The resulting strain Can004 produced 40.7 mg/L of canthaxanthin, which was 53% higher than the yield of Can003 (Tables 1, 2, Fig. 2A). At the same time, there was a significant reduction in the accumulation of the byproducts echinenone (from 4.21 to



3.6 mg/L) and β -carotene (from 8.62 to 3.87 mg/L). Consequently, Can004 was used as a platform to study the enzymatic properties of CrtZ from different organisms.

The substrate preference of PAcrtZ and PCrtZ

To investigate the substrate preference of PAcrtZ and PCrtZ, the corresponding genes were integrated into the *manA* sites of CAR032 and Can004, respectively. Two copies of PAcrtZ were used in Ast007 to increase astaxanthin production and decrease by-product accumulation as described before [14]. Therefore, one and two copies of PAcrtZ and PCrtZ were inserted into the *manA* sites of CAR032 and Can003, resulting in the strains Zea001-004 and Ast014-017, respectively (Additional file 1: Fig S1, Table 1).

Zea001 (CAR032 with one copy of PCrtZ) and Zea002 (CAR032 with two copies of PCrtZ) respectively produced 1.23 and 2.7 mg/L of zeaxanthin, while leaving a large amount of β -carotene (Fig. 3A, Additional file 1: Table S3). After integrating of one or two copies PAcrtZ, the resulting strains produced 16.78 and 36.74 mg/L zeaxanthin, respectively accounting for 21 and 93% of the total carotenoids (Figs. 2C, 3A, Additional file 1: Table S3). PAcrtZ from *P. agglomerans* therefore exhibited a substrate preference for β -carotene. On the contrary, PCrtZ from *Paracoccus* sp. PC1 showed weak activity in the conversion of β -carotene into zeaxanthin.

Ast014 (Can004 with one copy of PAcrtZ) and Ast016 (Can004 with one copy of PCrtZ) produced similar amounts of astaxanthin, which were 9.9 and 10.21 mg/L astaxanthin respectively (Fig. 3B, Additional file 1: Fig. S2). Ast017 (Can004 with two copies of PCrtZ) and

Ast015 (Can004 with two copies of PAcrtZ) produced 19.84 mg/L and 16.4 mg/L astaxanthin, respectively. The astaxanthin production of Ast017 was 21% higher than that of Ast015 (Fig. 3B, Additional file 1: Fig. S2).

The different culture conditions in shake flasks and a 5-L fermenter may lead to differences of product accumulation. To test this, Ast017 was cultivated in a 5-L fermenter at pH 7.0 to increase astaxanthin production and assess the by-product accumulation of adonirubin, canthaxanthin, echinenone or β -carotene. Strain Ast017 produced 1.1 g/L and 8 mg/g DCW of astaxanthin within 60h (Fig. 4), in addition to 1.1 g/L of canthaxanthin and 0.42 g/L of adonirubin as predominant by-products (Fig. 2D). Canthaxanthin and adonirubin are both substrates of CrtZ and could be converted into astaxanthin by this enzyme, which demonstrated that the expression of PCrtZ in Ast017 was insufficient.




Fig. 4 Fed-batch fermentation results for astaxanthin production by Ast017. Three independent experiments were performed for each strain, and the error bars represent the standard deviations




Fig. 3 Expression PCrtZ and PAcrtZ in platform strains. Three independent shake-flask fermentations were performed for each strain, and the error bars represent the standard deviations. A Cell growth and zeaxanthin production B Cell growth and astaxanthin production. The numbers of “+” in the tables indicate the numbers of corresponding *crtZ* in strains

Improving astaxanthin production by integrating additional copies of PCrtZ

The results of shake-flasks and bioreactor fermentation showed that two copies of PCrtZ were insufficient to convert all intermediates into astaxanthin. Accordingly, another copy or two copies of PCrtZ were integrated into the chromosome of Ast017 to obtain Ast018 and Ast019, respectively (Additional file 1: Fig. S1, Table 1). Ast018 produced 21.1 mg/L of astaxanthin, which was 21% higher than the yield of Ast017 (Fig. 3B, Additional file 1: Fig. S2). However, Ast019 (Ast017 with the addition of two copies of PCrtZ) produced 13.12 mg/L of astaxanthin, which was a 34% decrease compared with Ast017 (Fig. 3B, Additional file 1: Fig. S4). The fourth copy of PCrtZ presumably caused an increasing metabolic burden [18], which led to reduce the yield of astaxanthin under shake flasks conditions.

Gro046 was the best astaxanthin producing strain we constructed before and produced 1.18 g/L astaxanthin after 60 h of fed-batch fermentation, in which *crtZ* and *crtW* (including 2 copies of *PActZ* and 1 copy of *crtW*^{*}) (Table 1) were coordinately expressed and the molecular chaperone genes *groES-groEL* were regulated [14]. To investigate the effect of combined utilization of PCrtZ and PActZ on the astaxanthin yield, a copy of PCrtZ was inserted into the chromosome of Gro-46 (Fig. S1, Table 1) [14]. Furthermore, a copy of *crtW*^{*} was inserted into the chromosome of Gro-46 together with PCrtZ

in case *crtW*^{*} insufficiency affects the astaxanthin yield, since Ast017 contains two copy of *crtW*^{*} while Gro-46 only has a copy of *crtW*^{*}. The resulting strain Ast010 produced 24.5 mg/L of astaxanthin which was 16% higher than the yield of Ast018 (Fig. 3B, Additional file 1: Fig. S2).

Fed-batch fermentation of strains Ast018 and Ast010 for astaxanthin production

To further increase astaxanthin production, fed-batch fermentation of Ast018 and Ast010 was performed in a 5-L fermenter at pH 7.0. Ast018 produced 1.73 g/L and 12 mg/g DCW of astaxanthin within 70 h (Fig. 5AB), representing 57% and 50% increases over Ast0017, respectively. Additionally, 0.55 g/L of canthaxanthin and 0.29 g/L of adonirubin were accumulated as the major by-products, which was respectively 50% and 31% less than those in Ast017 (Fig. 5AB).

After 60 h of fed-batch fermentation, strain Ast010 produced 1.71 g/L and 12.9 mg/g DCW of astaxanthin (Fig. 5C), which was 45% and 65% higher than in Gro46 [14], respectively. The highest production of astaxanthin was 1.82 g/L after 67 h of fed-batch fermentation. Astaxanthin accounted for 65% of the total carotenoids and only small peaks representing other carotenoids appeared in the HPLC chromatogram (Fig. 5D).




Fig. 5 Fed-batch fermentation results for astaxanthin production by strains Ast018 and Ast010. Three independent experiments were performed for each strain, and the error bars represent the standard deviations. A Strain Ast018; B HPLC chromatograms of carotenoids produced by the strains Ast018; C Strain Ast010; D HPLC chromatograms of carotenoids produced by the strain Ast010. 1, β -carotene; 2, canthaxanthin; 3, echinenone; 4, lycopene; 5, astaxanthin; 6, adonixanthin

Discussion

The most suitable biosynthetic genes that enable the efficient channeling of available metabolic intermediates towards the desired product are important for the *in vivo* biosynthesis of complex natural products in a heterologous host. The catalytic activity of astaxanthin-producing enzymes derived from various species was compared in numerous studies [8, 9, 19–21]. Fraser et al. investigated characterization of the marine bacteria *CrtZ* and *CrtW* enzymes specific to astaxanthin biosynthesis and compared with the *CrtZ* from *P. anan-tis* and *CrtW* from *Haematococcus* BKT *in vitro* respectively. The results indicated that the *CrtZ* enzymes from *Paracoccus* sp. PC1 and *A. aurantiacum* preferentially converted canthaxanthin to astaxanthin, whereas the *CrtZ* from *P. anan-tis* had a propensity for the formation of zeaxanthin from β -carotene [10]. Furthermore, substrate inhibition of *crtZ* was observed at high substrate concentrations [22]. In this study, Zea004 which has two copies of *PAcrtZ* produced high level of zeaxanthin (36.74 mg/L in shake flasks). Notably, *P. agglomerans* and *P. anan-tis* belong to the same genus, so the *PAcrtZ* has similar enzymatic characteristics to *crtZ* from *P. anan-tis* (β -carotene preference and substrate inhibition). Furthermore, high levels of canthaxanthin (40.7 mg/L in shake flask fermentation and 3.9 g/L in fed-batch fermentation) were produced by Can004, which has two copies of *crtW** (Additional file 1: Fig. S3). The results demonstrated that *crtW* from *Brevundimonas* sp. SD212 has a preference for β -carotene. Astaxanthin accounted for 53% of the total carotenoids produced by Gro-46 (peak area of astaxanthin / peak area of total carotenoid), and the major by-products of adonirubin (8%), canthaxanthin (5%), echinenone (5%), lycopene (12%) and β -carotene (17%) were accumulated besides astaxanthin. The low-level accumulation of zeaxanthin and adonixanthin may indicate insufficient *CrtZ* expression in Gro-46 [14]. However, additional copies of *PAcrtZ* did not increase the astaxanthin yield. We speculated that *PAcrtZ* preferentially converts β -carotene into zeaxanthin, and cannot easily convert ketocarotenoids into astaxanthin. Accordingly, the low ratio of astaxanthin to total carotenoids in Gro-46 was probably caused by the substrate preference and substrate inhibition of *PAcrtZ*. To assess its substrate preference, *PCcrtZ* was expressed in platform stains producing β -carotene and canthaxanthin, respectively. Low levels of zeaxanthin was got by expressing *PCcrtZ* in CAR032, while high levels of astaxanthin was produced by expressing *PCcrtZ* in Can004, which suggested that *PCcrtZ* has a substrate preference for canthaxanthin over β -carotene, which was consistent with earlier reports.

Ast018 with three copies of *PCcrtZ* and two copies of *crtW* produced 1.73 g/L of astaxanthin, while Ast019

containing four copies of *PCcrtZ* and two copies of *crtW** produced 1.75 g/L of astaxanthin along with certain amounts of canthaxanthin and adonirubin in fed-batch fermentation (Fig. 4, Additional file 1: Fig. S3). The fourth *PCcrtZ* in Ast019 therefore did not reduce accumulation of canthaxanthin and adonirubin, presumably due to substrate inhibition.

To investigate the effect of combined utilization of *PCcrtZ* and *PAcrtZ* on the astaxanthin yield, *PCcrtZ* and *PAcrtZ* were co-expressed in Ast010. Ast010 produced 1.82 g/L and 11.5 mg/g DCW of astaxanthin after 67 h of fed-batch fermentation, whereby astaxanthin accounted for more than 65% of the total carotenoids. The peaks of all other carotenoids were much smaller than that of astaxanthin, demonstrating that the combination of *CrtZ* orthologs with complementary substrate preferences can effectively improve the yield and purity of astaxanthin. To our best knowledge this strategy was used for the synthesis of astaxanthin for the first time in this study.

It was reported that the coordinated expression of *crtZ* and *crtW* led astaxanthin as the only carotenoid product [13]. However, the peak area of astaxanthin among the carotenoid products of Ast010 was only 65% of the total. The low ratio of astaxanthin synthesized by Ast010 has two possible explanations. First, it is possible that some unusual intermediates were accumulated. Because the carotenoid synthesis pathway and central metabolic pathways of the platform strains used in this study were optimized [15, 16, 23], a large amount of lycopene and β -carotene were synthesized. Notably, small amount of γ -carotene was accumulated as a by-product of β -carotene synthesis (a small peak between 1 and 3 in Fig. 2A, the γ -carotene is undetectable when β -carotene production is low). The corresponding hydroxylated and ketylation products cannot be further converted to astaxanthin and consequently accumulated. Secondly, substrate inhibition makes the catalytic reaction incomplete. Substrate inhibition of *CrtZ* and *CrtW* was reported previously, blocking the further conversion of intermediate derived from β -carotene into astaxanthin. Higher substrate concentrations would lead to the accumulation of more intermediates such as adonirubin, canthaxanthin, and echinenone. Certainly, more efforts in modifying recombinant strain by metabolic engineering and optimizing fermentation condition may increase the yield and purity of astaxanthin.

Multiple copies of *crtZ* and *crtW** were used to improve astaxanthin production in Ast010 and Ast017, which probably implied that the specific activity of *CrtZ* and *CrtW** is low. Excessive overexpression of heterologous genes can lead to a metabolic burden or protein misfolding, as well as non specific side reactions [24]. Therefore, increasing the specific activity of *CrtZ* and

CrtW*, and accordingly decreasing the copy number of *crtZ* and *crtW** may be an effective strategy to increase astaxanthin production and reduce the accumulation of by-products. The PCcrtZ and PAcrtZ enzymes convert the same substrates, but have different substrate preferences. In future studies, homology modeling and analysis of the active sites of these two enzymes, which may elucidate the structural basis of their substrate, could be used for further rational engineering of CrtZ by site-directed mutagenesis.

Conclusions

To the best of our knowledge, we report the highest astaxanthin obtained in engineered *E. coli* to date. The combined utilization of CrtZ orthologs with different substrate preferences can enhance the production of astaxanthin and increase the ratio of astaxanthin among total carotenoids.

Materials and methods

Strains, media and growth conditions

All strains used in this study are listed in Table 1; their construction is depicted in Additional file 1: Fig. S1 and described in detail below. The plasmids used are presented in Additional file 1: Table S2, and primers in Additional file 1: Table S1. During strain construction, the cultures were grown aerobically at 30°C, 37°C, or 39°C in Luria Bertani (LB) medium. For carotenoid production, single colonies were picked from the plate and grown in tubes containing 4 mL of LB at 30°C and 250 rpm overnight. The resulting seed cultures were used to inoculate 100-mL flasks containing 20 mL of LB with 2% glycerol to an initial OD₆₀₀ of 0.05, and grown at 30°C and 250 rpm. After 24 h of growth, the cells were collected for measurement of carotenoid production.

Construction of plasmids for the expression of heterologous *crtZ* genes

Plasmids were assembled using the Seamless Cloning Kit (Beyotime, China). To determine the effects of *crtZ* from different organisms on the production of astaxanthin, plasmids psc104-*crtZ* and psc104-PCcrtZ were constructed. The PAcrtZ gene was amplified from *P. agglomerans* CGMCC No.1.2244 (GenBank accession number HQ003247) using the primer pair CrtZ-RBS-99 A-CPEC-F/CrtZ-CPEC-R (Additional file 1: Table S1), and the plasmid backbone was amplified from pSC103 using the primer pair 99 A-CPEC-F/99A-CPEC-R. Then, the two PCR fragments were ligated using the Seamless cloning kit (Beyotime), resulting in the plasmid pSC104-*crtZ*. The PCcrtZ was synthesized by Genscript Inc according to the sequence of *crtZ* from *Paracoccus* sp. PC1 (GenBank accession number: D58422), and was

amplified using the primer pair PC-*crtZ*-CPEC-RBS-F/PC-*crtZ*-CPEC-R (Additional file 1: Table S1). Then it was ligated with plasmid backbone, resulting in plasmid pSC104-PCcrtZ.

Integration of the heterologous genes into the *E. coli* chromosome

All *E. coli* gene insertions were performed using two-plasmid CRISPR/Cas9 technology as reported previously [14, 25]. The construction of donor plasmids (Additional file 1: Table S2) were described in Additional file 1: Text S1. The primers used for gene integration is listed in Additional file 1: Table S1.

Integration of *crtZ* was described as an example to show how to integrate heterologous genes into the *E. coli* chromosome. The helper plasmid pCas9 and donor plasmid pManA-*crtZ* were co-electroporated into the β -carotene producing strain CAR032, and the resulting strain was processed using the Cas9 genome-editing protocol as described previously [25–27], yielding the strain Zea001 with a PCcrtZ integration at the *manA* site. Zea002, Zea003, and Zea004 were obtained by inserting PCcrtZ-PCcrtZ, PAcrtZ or PAcrtZ-PAcrtZ into the chromosome of CAR032 at the *manA* site respectively, using the same method.

Fed-batch fermentation of strains Ast017, Ast018 and Ast010

Strains Ast017, Ast018 and Ast010 were used for producing astaxanthin through fed-batch fermentation. Two stage systems were used for preparing seed. The first seed was prepared by inoculating fresh colonies into a 100 mL flask containing 10 mL medium at 30°C with shaking at 250 rpm until OD₆₀₀ was 0.7–1.0. Then 3 mL of culture from first seed stage was added to a 500 mL flask containing 120 mL medium and incubated at 30°C with shaking at 250 rpm until OD₆₀₀ reached 1.5. The second seed solution was transferred to a 5 L fermentation tank containing 3 L substrate medium. The fermentation substrate medium and fermentation progress were the same as those described previously [14].

Measurement of carotenoid production

Carotenoids were extracted using acetone as described before [15]. A sample comprising 200 μ L of the culture broth was harvested by centrifugation at 13,800 \times g for 5 min, resuspended in 1 mL of acetone, and incubated at 55°C for 15 min in the dark. The samples were then centrifuged at 13,800 \times g for 10 min to obtain the supernatant containing carotenoids, which was used for HPLC analysis.

The analytes were separated on a Symmetry C18 column (250 mm \times 4.6 mm, 5 μ m, Waters, Ireland), which

was kept at 30°C, and were detected at 476 nm using a Shimadzu UV-2550 spectrophotometer (Shimadzu, Kyoto, Japan). The mobile phase and flow rate in measurement of carotenoids production were the same as that described previously [14]. The results represent the means \pm SD of three independent experiments. Dry cell weight (DCW) was calculated from the optical density at 600 nm (OD_{600}) using the empirical formula $1 OD_{600} = 0.323 \text{ g DCW L}^{-1}$.

Supplementary information

The online version contains supplementary material available at <https://doi.org/10.1186/s12934-022-01798-1>.

Additional file : Text S1 Construction of plasmids for the chromosomal integration of heterologous genes. **Text S2** The amino acid sequences of PCrtZ. **Text S3** The amino acid sequences of PaCrtZ. **Table S1.** Primers used in this study. **Table S2.** Plasmids used in this study. **Table S3.** Carotenoids production by strains producing Zeaxanthin in shake flasks. **Fig. S1.** Flowchart illustrating the construction of the main strains used in this study. **Fig. S2.** Carotenoids production of antxanthin producing strains. **Fig. S3.** Fed-batch fermentation results for canthaxanthin production by strains Can004. **Fig. S4.** Fed-batch fermentation results for astaxanthin production by strains Ast019.

Author contributions

MZ: Data curation, Formal analysis, Writing - original draft. ZG: Data curation, Methodology. JT: Data curation. FL: Conceptualization, Formal analysis. QYL: Supervision, Funding acquisition, Writing - original draft. XLZ: Supervision, Funding acquisition.

Funding

This work was supported by the National Key R&D Program of China [grant numbers 2019YFA0905700], and the National Natural Science Foundation of China [Grant Numbers 31770059 and 31770105].

Availability of data and materials

All data generated or analysed during this study are included in this published article and its Additional file 1: information fles.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare that they have no competing interests.

Author details

¹College of Biotechnology, Tianjin University of Sciences and Technology, Tianjin 300457, China. ²Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, 32 Xiqidao, Tianjin Airport Economic Park, Tianjin 300308, China. ³Key Laboratory of Systems Microbial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China. ⁴National Technology Innovation Center of Synthetic Biology, Tianjin 300308, China. ⁵University of Chinese Academy of Sciences, Beijing 100071, China.

References

- Barredo JL, Garcia-Estrada C, Kosalkova K, Barreiro C. Biosynthesis of Astaxanthin as a Main Carotenoid in the *Heterobasidiomyces* Yeast *Xanthophyllomyces dendrorhous*. *J Fungi (Basel)*. 2017; 3(3):44–60.
- Johnson EJ. Role of lutein and zeaxanthin in visual and cognitive function throughout the lifespan. *Nutr Rev*. 2014; 72:605–612.
- Krinsky NI, Landrum JT, Bone RA. Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. *Annu Rev Nutr*. 2003; 23:171–201.
- Wallace TC. A Comprehensive Review of Eggs, Choline, and Lutein on Cognition Across the Life-span. *J Am Coll Nutr*. 2018; 37:269–285.
- Chew BP, Park JS, Wong MW, Wong TS. A comparison of the anticancer activities of dietary beta-carotene, canthaxanthin and astaxanthin in mice *in vivo*. *Anticancer Res*. 1999; 19:1849–1853.
- Ambati RR, Phang SM, Ravi S, Aswathanarayana RG. Astaxanthin: sources, extraction, stability, biological activities and its commercial applications—a review. *Mar Drugs* 2014, 12:128–152.
- Choi S, Koo S. Efficient syntheses of the keto-carotenoids canthaxanthin, astaxanthin, and astacene. *J Org Chem*. 2005; 70:3328–3331.
- Scaife MA, Burja AM, Wright PC. Characterization of cyanobacterial beta-carotene ketolase and hydroxylase genes in *Escherichia coli*, and their application for astaxanthin biosynthesis. *Biotechnol Bioeng*. 2009; 103:944–955.
- Scaife MA, Ma CA, Ninlayarn T, Wright PC, Armenta RE. Comparative analysis of beta-carotene hydroxylase genes for astaxanthin biosynthesis. *J Nat Prod*. 2012; 75:1117–1124.
- Fraser PD, Miura Y, Misawa N. *In vitro* characterization of astaxanthin biosynthetic enzymes. *J Biol Chem*. 1997; 272:6128–6135.
- Tao L, Wilczek J, Odom JM, Cheng Q. Engineering a beta-carotene ketolase for astaxanthin production. *Metab Eng*. 2006; 8:523–531.
- Ye RW, Stead KJ, Yao H, He H. Mutational and functional analysis of the beta-carotene ketolase involved in the production of canthaxanthin and astaxanthin. *Appl Environ Microbiol*. 2006; 72:5829–5837.
- Lemuth K, Steuer K, Albermann C. Engineering of a plasmid-free *Escherichia coli* strain for improved *in vivo* biosynthesis of astaxanthin. *Microb Cell Fact*. 2011; 10:29.
- Gong Z, Wang H, Tang J, Bi C, Li Q, Zhang X. Coordinated Expression of Astaxanthin Biosynthesis Genes for Improved Astaxanthin Production in *Escherichia coli*. *J Agric Food Chem*. 2020; 68:14917–14927.
- Zhao J, Li Q, Sun T, Zhu X, Xu H, Tang J, Zhang X, Ma Y. Engineering central metabolic modules of *Escherichia coli* for improving beta-carotene production. *Metab Eng*. 2013; 17:42–50.
- Ye L, He P, Li Q, Zhang X, Bi C. Type IIs restriction based combinatory modulation technique for metabolic pathway optimization. *Microb Cell Fact*. 2017; 16:47.
- Li Z, Chen Q, Tang J, Li Q, Zhang X. Integrating balanced mevalonate pathway into chromosome for improving lycopene production in *Escherichia coli*. *Sheng Wu Gong Cheng Xue Bao*. 2019; 35(3):404–14.
- Wu G, Yan Q, Jones JA, Tang YJ, Fong SS, Koffas MAG. Metabolic burden: cornerstones in synthetic biology and metabolic engineering applications. *Trends Biotechnol*. 2016; 34:652–64.
- Li XR, Tian GQ, Shen HJ, Liu JZ. Metabolic engineering of *Escherichia coli* to produce zeaxanthin. *J Ind Microbiol Biotechnol*. 2015, 42:627–636.
- Lu Q, Bu YF, Liu JZ. Metabolic engineering of *Escherichia coli* for producing astaxanthin as the predominant carotenoid. *Mar Drugs*. 2017; 15(10):296.
- Zhang CQ, Seow VY, Chen XX, Too HP. Multidimensional heuristic process for high-yield production of astaxanthin and fragrance molecules in *Escherichia coli*. *Nat Commun*. 2018; 9(1):1–12.
- Fraser PD, Shimada H, Misawa N. Enzymic confirmation of reactions involved in routes to astaxanthin formation, elucidated using a direct substrate *in vitro* assay. *Eur J Biochem*. 1998; 252:229–236.
- Sun T, Miao L, Li Q, Dai G, Lu F, Liu T, Zhang X, Ma Y. Production of lycopene by metabolically-engineered *Escherichia coli*. *Biotechnol Lett*. 2014; 36:1515–1522.
- Albermann C. High versus low level expression of the lycopene biosynthesis genes from *Pantoea ananatis* in *Escherichia coli*. *Biotechnol Lett*. 2011; 33:313–319.
- Zhao D, Yuan S, Xiong B, Sun H, Ye L, Li J, Zhang X, Bi C. Development of a fast and easy method for *Escherichia coli* genome editing with CRISPR/Cas9. *Microb Cell Fact*. 2016; 15:205.

Received: 4 March 2022 Accepted: 13 April 2022
Published online: 25 April 2022

26. Datsenko KA, Wanner BL. One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc Natl Acad Sci USA*. 2000; 97:6640–6645.
27. Jiang W, Bikard D, Cox D, Zhang F, Marraffini LA. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. *Nat Biotechnol*. 2013; 31:233–239.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

